
PF-9363
CAS No. 2569009-58-9
PF-9363( CTX-3648 )
Catalog No. M24156 CAS No. 2569009-58-9
PF-9363 is a potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 147 | In Stock |
![]() ![]() |
10MG | 237 | In Stock |
![]() ![]() |
25MG | 375 | In Stock |
![]() ![]() |
50MG | 500 | In Stock |
![]() ![]() |
100MG | 696 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePF-9363
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-9363 is a potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer.
-
DescriptionPF-9363 is a potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer.
-
In VitroPF-9363 (0~1 μM; 1 day; ZR75-1, T47D and MCF7 cells) down-regulates the expression of H3K23Ac biomarker.PF-9363 leads to down regulation of a specific set of genes involved in ESR1 pathway, cell cycle and stem cell pathways. PF-9363 shows that the IC50 values for ZR75-1 and T47D are 0.3 nM and 0.9 nM. Western Blot Analysis Cell Line:ZR75-1, T47D and MCF7 cells Concentration:0~1 μM Incubation Time:1 day Result:Down-regulated the expression of H3K23Ac biomarker.
-
In VivoPF-9363 shows strong anti-tumor activity in patient-derived xenograft models.
-
SynonymsCTX-3648
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorKAT6A/KAT6B
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2569009-58-9
-
Formula Weight444.46
-
Molecular FormulaC20H20N4O6S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (112.50 mM)
-
SMILESO=S(C1=C(OC)C=CC=C1OC)(NC2=NOC3=C2C(OC)=CC(CN4N=CC=C4)=C3)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Shikhar S, et al. First-in-class KAT6A/KAT6B Inhibitor CTx-648 (PF-9363) Demonstrates Potent Anti-tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation
molnova catalog



related products
-
EZM0414
EZM0414 is a selective SEDT2 inhibitor that is mostly used to study diffuse large B lymphocytoma and recurrent or refractory multiple myeloma.
-
MRTX-1719
MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC 50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells.
-
CBB3001
CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM.